08:30-10:00
P.2.1 Age related macular Degeneration. - Moderator: Jóhann Ragnar Guðmundsson

08:30-08:50
The MacuStar project - Robert Finger, Department of Ophthalmology, University of Bonn, Germany - Confirmed

08:50 – 09:05
AMD research at Oslo University Hospital: from LUCAS to compounding pharmacy and beyond.
Speaker: Professor Morten Carstens Moe, Oslo University Hospital, Oslo, Norway. Confirmed

09:05 – 09:15 Off-label use of Avastin: Scandinavian disparities.
Speaker: Tomas Bro, MD, PhD, Höglandssjukhuset, Eksjö, Sweden Confirmed

09:15 – 09:25 The risk of extending AMD treatment.
Speaker: David Epstein, MD, PhD. Sankt Erik Eye Hospital, Karolinska Institute, Stockholm, Sweden. ? Restrictions for travel

09:25 – 09:35 The Swedish Macula Register.
Speaker: Inger Westborg, MD, PhD., Uppsala University Hospital, Uppsala, Sweden. Confirmed

09:35 – 09:50 AMD Epidemiology and Genetics. What is important!
Speaker: Prof. emeritus Friðbert Jónasson, University of Iceland, Iceland. Confirmed. There will be a change of the title

09:50 – 10:00 QnA.

08:30 – 10:00 L.2.1 Retinal degenerations. Clinical aspects.

Moderator: Dr. Prof. Elise Heon, The Hospital for Sick Children, Toronto, Canada.Confirmed

08:30 – 08:50 Clinical aspects of IRD.
Speaker: Prof. Dr. Elise Heon The Hospital for Sick Children, Toronto, Canada. Confirmed

08:50 – 09:10 Clinical aspects of inherited macular degenerations.
Speaker: Dr. Line Kessel, Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark. Confirmed

09:10 – 09:30 Syndromic forms of IRD.
Speaker: prof. Dr. Hélène Dollfus, CARGO, Hôpitaux Universitaires de Strasbourg, France. Confirmed

09:30 – 09:50 The genetic testing landscape
Speaker: Avril Daly, Retina International, Dublin, Ireland Confirmed

09:50 – 10:00 QnA.

10:00 – 10:30 Coffee break.

10:30 – 11:30 P.2.2 Assessment of Endpoints in clinical studies.

Moderators Dr. Cecilie Bredrup, Bergen, Norway and Prof. Sten Kjellström, Lund, Sweden. Confirmed

10:30 – 10:50 Experiences with Luxturna.
Speaker: Prof.Line Kessel, Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark Confirmed

10:50 – 11:10 Paediatric specificities in trials.
Speaker: Prof. Dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada. Confirmed

11:10 – 11:30 Developing Patient Relevant Outcomes in Gene Therapy Trials: The Novel Functional Vision Endpoint, the Multi-luminance Mobility Test (MLMT).

Speaker: Dr. Daniel Chung, DO, MA, Philadelphia, USA Confirmed Daniel.chung@sparingvision.com

Where to put gene agnostic approaches?

10:30 – 11:30 L.2.2 Retinal degenerations – the genetics.

Moderator: Prof. Jón Jóhannes Jónsson, national University Hospital, Reykjavík, Iceland. Confirmed

10:30 – 10:50 Pattern of inheritance – easy to understand.
Speaker: Dr. Eirný Þórólfsdóttir National University Hospital, Reykjavík, Iceland. Confirmed

10:50 – 11:10 Understanding the results – a difficult task.
Speaker: Prof. Jón Johannes Jónsson, national University Hospital, Reykjavík, Iceland.Confirmed

11:10 – 11:20 Lessons from Iceland on the diversity of genetic causes. Speaker: Daníel Þorsteinsson. Confirmed

11:20 – 11:30 ABCA4 related IRDs
Speaker: Frans Cremers, Radboud University, Nijmegen, Netherlands Confirmed

11:30 – 12:00 K.2.1 Keynote: Scientific results, a rollercoaster between hope and deception.
Speaker: Christina Fasser, former president of the Retina International, Zurich, Switzerland. Confirmed

12:00 – 13:30 Lunch

13:30 – 14:00 K.2.2
Keynote: Innovations in Ophthalmology.
Dr. Sabri Markabi NOT confirmed. Masayo Takahashi?Yes, switch with Christina

14:00 – 15:00 P.2.3 Phenotype-Genotype Correlations in IRD

Moderators: Josephine Prener Holtan MD, Oslo University Hospital, Oslo, Norway, and Prof. Bart Leroy, Ghent, Belgium. Confirmed

14.00 – 14.10 Natural history and clinical characterization of patients with retinitis pigmentosa caused by mutations in the PRPF31 gene.
Speaker: Kristian Lisbjerg, MD, Department of Ophthalmology, Copenhagen University Hospital, Denmark.Confirmed

14.10 – 14.20 Genetic basis and phenotypic characterization of Danish patients with Achromatopsia.
Speaker: Mette K.G. Andersen,MD, Ophthalmologist at Department of Ophthalmology, Copenhagen University hospital, Rigshospitalet-Glostrup, Denmark.Confirmed

14.20 – 14.35 Whole exome sequencing in the diagnosis of hereditary retinal disorders: A clinical perspective.
Speaker: Ragnhild Jansson Wivestad, MD, Department of Ophthalmology, Haukeland University Hospital, Norway. Confirmed

14.35 – 15.00 ERN-EYE a booster for patients care and research for Rare Eye Diseases in Europe.
Speaker: Professor Helene Dollfuss, MD, PhD, Service de Génétique Médicale, Hôpital de Hautepierre, Strasbourg, France. Confirmed

14:00 – 15:00 L.2.3 Basics of stem cell and gene-based therapies.

Moderator: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA Confirmed 14:00 – 14:20 Overview of on-going clinical trials with stem cells

Speaker: Prof. Goran Petrovski.Confirmed 14:20 – 14:35 Stem Cell Based Trials for AMD

Speaker: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA Confirmed 14:35 – 14:50 Clinical trial in opto-genetics.

Speaker: Prof. Isabelle Audo, INSERM, Paris, France. Confirmed
14:50 – 15:00 How to discriminate between real treatments offers and quacks.

Speaker: Martin Smedstad Oslo, Norway. Change title 15:00 – 15:30 Coffee break.

15:30 – 16:00 K.2.3
Keynote: Restoration of vision
Speaker: Prof. Mark S. Humayun University of Southern California, Los Angeles, USA. Confirmed

16:00 – 17:00 P.2.4. Innovations in Ophthalmology.

Moderators: Christina Fasser and Prof. Einar Stefánsson. Program not ready

16:00 – 17:00 L.2.4 Rehabilitation and mobility training. Session confirmed Moderators: Vala Jóna Garðarsdóttir and Rósa María Hjörvar Iceland.